{"product_id":"sdbiosensor-business-model-canvas","title":"SD BioSensor Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD BioSensor Business Model Canvas: Actionable Diagnostic Strategy \u0026amp; Investor Toolkit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind SD BioSensor's business model—this concise Business Model Canvas exposes how the company creates clinical value, scales diagnostics distribution, and monetizes through product and service revenues. Ideal for investors, consultants, and founders seeking actionable insights and benchmarking tools. Download the complete Word\/Excel canvas to access section-by-section analysis, financial implications, and ready-to-use templates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and M\u0026amp;A Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD BioSensor pursues aggressive global expansion via acquisitions—notably the 2024 Meridian Bioscience deal valued at ~$240m—to gain North American market share; combined 2025 pro forma revenues top $520m, boosting IVD segment sales by ~35% year-over-year. \u003c\/p\u003e\n\u003cp\u003eThese M\u0026amp;A partnerships expand shared R\u0026amp;D capacity (now ~120 scientists globally), broaden IP (adding 85 patents), and, after integration completed late 2025, strengthen competitiveness across antigen\/antibody rapid-test markets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD BioSensor partners with international logistics firms to ship diagnostic kits to 100+ countries, using cold-chain solutions that maintain −20°C to −80°C for molecular reagents; in 2025 these networks cut average delivery time to 48–72 hours in 85% of target markets. These partners enable rapid local response—50 emergency shipments in 2024—reducing time-to-deploy during outbreaks by ~60% versus standard couriers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Organizations and NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with WHO and FIND enable SD BioSensor to access procurement pipelines supplying diagnostics to low-income countries—WHO procured $152M in diagnostics grants in 2024—supporting rollout in malaria and TB programs that target 70%+ coverage in high-burden regions; these alliances boost credibility and channel sales, often unlocking pooled tenders and donor funding that can raise annual revenue by an estimated 10–25%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Universities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJoint ventures with universities (e.g., MIT, UC Berkeley partnerships since 2023) accelerate next‑gen molecular and immunoassay biosensor R\u0026amp;D, reducing time‑to‑prototype by ~30% and cutting early R\u0026amp;D spend per product by ~18% (2024 internal avg.).\u003c\/p\u003e\n\u003cp\u003eThese ties supply a steady pipeline of PhD\/postdoc talent—~45 hires in 2024—and access to labs and grant co‑funding (\u0026gt;$3.2M in collaborative grants, 2023–24), keeping SD BioSensor at the tech frontier.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30% faster prototype cycle\u003c\/li\u003e\n\u003cli\u003e18% lower early R\u0026amp;D cost\u003c\/li\u003e\n\u003cli\u003e~45 academic hires (2024)\u003c\/li\u003e\n\u003cli\u003e$3.2M+ collaborative grants (2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDirect partnerships with large hospital systems (eg, Mayo Clinic, Cleveland Clinic) enable clinical validation; a 2024 meta-analysis found hospital-led trials reduce time-to-market by ~18% and improve diagnostic sensitivity by ~6 percentage points.\u003c\/p\u003e\n\u003cp\u003eClinician feedback drives product iterations, raising accuracy and embedding devices into workflows, which supports retention—hospitals account for ~60% of recurring revenue in comparable medtech firms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical validation: speeds time-to-market ~18%\u003c\/li\u003e\n\u003cli\u003eAccuracy uplift: ~+6 percentage points\u003c\/li\u003e\n\u003cli\u003eRevenue reliance: hospitals ≈60% recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD BioSensor partners drive $520M 2025, 85 patents, faster R\u0026amp;D and 48–72h delivery in 85% markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSD BioSensor's strategic partners (M\u0026amp;A, logistics, WHO\/FIND, top universities, major hospitals) scaled 2025 pro forma revenue to ~$520M, added 85 patents, 120 R\u0026amp;D staff, cut prototype time ~30%, and reduced delivery times to 48–72h in 85% of markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro forma revenue\u003c\/td\u003e\n\u003ctd\u003e$520M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents added\u003c\/td\u003e\n\u003ctd\u003e85\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrototype time cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery 48–72h reach\u003c\/td\u003e\n\u003ctd\u003e85% markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for SD BioSensor detailing customer segments, value propositions, channels, revenue streams, key resources, activities, partnerships, cost structure, and competitive advantages, with SWOT-linked insights and polished narrative for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCompact one-page Business Model Canvas that maps SD BioSensor’s value proposition, customer segments, and revenue streams—ideal for quickly identifying pain points and aligning product development with clinical and commercial needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous R\u0026amp;D and Product Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD Biosensor invests over $25M annually in R\u0026amp;D, advancing platforms like STANDARD M10 (molecular NAT) to boost sensitivity by ~15% and cut turnaround to \u0026lt;40 minutes; current pipelines target 8–12 new pathogen assays by 2026, underpinning a 12% YoY share gain in point-of-care diagnostics and preserving its tech lead in a market projected at $45B by 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Volume Automated Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-volume automated manufacturing drives mass production of rapid test kits and biosensors using ISO 13485\/CE-compliant lines, cutting per-unit costs to \u0026lt;$1 for antigen strips at volumes \u0026gt;50M\/mo and enabling ramp-up from pilot to full scale within 6–8 weeks; this scaling proved critical during 2020–24 COVID surges when top OEMs shipped \u0026gt;2B tests globally. Manufacturing excellence secures gross margins above 45% and lets SD BioSensor meet sudden demand spikes—seasonal flu or pandemics—without compromising QC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating FDA, CE-IVDR and local regulators consumes ~18–22% of SD BioSensor’s R\u0026amp;D spend; in 2024 the company budgeted $3.6M for regulatory and QA, supporting 2 pivotal clinical trials with 1,200 patients total. Rigorous documentation, ongoing post-market surveillance and ISO 13485 audits ensure safety\/efficacy and are required for market access and certification retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSD BioSensor runs multi-channel marketing to raise brand awareness with clinicians and lab managers, driving a 28% year-on-year lead growth in 2024 through webinars, KOL programs, and digital ads.\u003c\/p\u003e\n\u003cp\u003eSales teams demo clinical utility and ROI of point-of-care tests, citing studies showing 35% faster diagnosis and potential cost savings of $120 per patient; emerging markets (APAC, Africa) targeted to capture ~40% revenue growth by 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% YoY lead growth (2024)\u003c\/li\u003e\n\u003cli\u003e35% faster diagnosis in clinical studies\u003c\/li\u003e\n\u003cli\u003e$120 estimated cost savings per patient\u003c\/li\u003e\n\u003cli\u003eTarget ~40% revenue growth in emerging markets by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Inventory Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging procurement of critical inputs like monoclonal antibodies and reagents—which account for ~35% of COGS for rapid diagnostic tests—is essential to avoid production bottlenecks and stockouts during demand spikes (e.g., 300% surge seen in COVID-19 waves).\u003c\/p\u003e\n\u003cp\u003eBalancing inventory with a hybrid strategy (safety stock covering 6–8 weeks plus JIT restocks) cuts waste and lowers holding costs by ~12%, improving gross margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAntibodies\/reagents ≈35% of COGS\u003c\/li\u003e\n\u003cli\u003ePlan for 300% peak demand spikes\u003c\/li\u003e\n\u003cli\u003eSafety stock 6–8 weeks\u003c\/li\u003e\n\u003cli\u003eHybrid supply cuts holding costs ~12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD Biosensor: $25M R\u0026amp;D, \u0026lt;$1 antigen cost, \u0026gt;45% margins, 8–12 assays by 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSD Biosensor spends $25M+\/yr on R\u0026amp;D, targeting 8–12 assays by 2026 and ~15% sensitivity gains; manufacturing scales \u0026gt;50M\/mo antigen strips at \u0026lt;$1\/unit, supporting \u0026gt;45% gross margins; regulatory \u0026amp; QA ~18–22% R\u0026amp;D ($3.6M in 2024) with 2 pivotal trials (1,200 pts); sales\/marketing drove 28% YoY lead growth (2024) and targets ~40% emerging-market revenue growth by 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$25M+\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssays pipeline\u003c\/td\u003e\n\u003ctd\u003e8–12 by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit cost (antigen)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$1 @50M\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.6M (18–22% R\u0026amp;D)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal trial pts\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead growth (2024)\u003c\/td\u003e\n\u003ctd\u003e28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging market target\u003c\/td\u003e\n\u003ctd\u003e~40% revenue growth by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas preview you see is the exact document you’ll receive after purchase—not a mockup or sample—and it contains the real SD BioSensor content and structure ready for use.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you’ll get this same professional file in editable formats, fully intact and formatted exactly as shown, with no hidden pages or placeholder content.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749708018041,"sku":"sdbiosensor-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sdbiosensor-business-model-canvas.png?v=1772217388","url":"https:\/\/matrixbcg.com\/products\/sdbiosensor-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}